a median of 1.18/uL (range 0.20/uL-2.54/uL) and the ANC a median of 158/uL (range 0-1168/uL); 36/65 (55%) patients in DGD received no G-CSF (at physician's discretion) and those who received the drug did so starting on day 14 (median) post-transplant (range ¼11d-18d). There was no difference in the incidence or duration of grade III mucositis, weight gain, rash or engraftment syndrome between DGD and CGD groups. However, as shown in Table 1 the CGD group had significantly faster engraftment, abbreviation of neutropenia, diminished antibiotics use, and shorter hospitalization. These effects were independent of CD 34 cell dose. Primarily because of abbreviated hospital stay, there was a 17% cost benefit to the use of CGD, supporting the overall benefit of this treatment regimen for patients with MM who receive ASCT.
a median of 1.18/uL (range 0.20/uL-2.54/uL) and the ANC a median of 158/uL (range 0-1168/uL); 36/65 (55%) patients in DGD received no G-CSF (at physician's discretion) and those who received the drug did so starting on day 14 (median) post-transplant (range ¼11d-18d). There was no difference in the incidence or duration of grade III mucositis, weight gain, rash or engraftment syndrome between DGD and CGD groups. However, as shown in Table 1 the CGD group had significantly faster engraftment, abbreviation of neutropenia, diminished antibiotics use, and shorter hospitalization. These effects were independent of CD 34 cell dose. Primarily because of abbreviated hospital stay, there was a 17% cost benefit to the use of CGD, supporting the overall benefit of this treatment regimen for patients with MM who receive ASCT. The Autologous Hematopoietic Stem Cell Transplantation (AHSCT) is a therapeutic method used in various immunological, hematological and genetic disorders, which uses patient's own stem cells collected from peripheral blood after their (the stem cells) mobilization by granulocyte colony-stimulating factors (GCS-F), in order to restore the damaged or defective bone marrow function. Oxidative stress and antioxidant depletion have been described during the stages involved in AHSCT. Glutathione peroxidase is an enzyme responsible for detoxification of organic and inorganic peroxides, which participates of enzymatic cellular antioxidant defense. The aim of the study was to evaluate the levels of glutathione peroxidase in various stages involving AHSCT in patients undergoing autologous hematopoietic stem cell transplantation. Glutathione peroxidase was determined using the Glutathione Peroxidase Ransel Ò kit (Randox). We measured glutathione peroxidase levels of eight patients at different times pre-and post-AHSCT: before Conditioning Regimen (CR), 24 hours after chemotherapy, 10 days (D +10) and 20 days (D +20) after transplantation. There was a statistically significant difference in levels of glutathione peroxidase after CR comparing to other times, suggesting an increase in oxidative stress after chemotherapy. According to previous studies, oxidative stress occurs acutely after high-dose chemotherapy for AHSCT and is apparently related to late hematological recovery. Thus, it can be suggested the use of glutathione peroxidase levels, and other oxidative stress parameters as toxicity and grafting markers after AHSCT.
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A 2 ) (ID-CY) and G-CSF when compared to low-dose CY
(1-2 gm/m 2 )-based strategies, has been shown to have a favorable risk/benefit profile in multiple myeloma (MM) patients (pts) receiving novel induction therapies. However the relative efficacy of ID-CY as compared to plerixafor (P) in PBPC mobilization in MM pts is not known. Herein we report outcomes of ID-CY/G-CSF mobilization compared to P/ G-CSF mobilization in MM pts treated with novel inductionregimens.
Methods: This multicenter outcomes study includes 84 pts who underwent a planned, single autograft within 1-year of starting induction therapy with novel chemotherapy agents (thalidomide, lenalidomide, bortezomib). Consecutive pts undergoing mobilization with ID-CY/G-CSF (3-4 gm/m 2 ) (n¼55) at one institution were compared against consecutive pts receiving plerixafor/G-CSF (0.24 mg/kg) (n¼29) at a different transplant center. In order to assess efficiency of PBPC mobilization, we evaluated peak peripheral blood (PB) CD34+ cell counts, CD34+ cell yield on day1 of collection, total CD34+ cell collection, and total number of apheresis sessions. Mobilization failure was defined as failure to collect 2 x10 6 cells/kg body weight.
All pts with normal renal function received uniform conditioning with Mel200 (MEL140 if serum creatinine was 2 mg/dl). Results: At baseline, the ID-CY and P cohorts were well balanced. No difference was observed in the use of lenalidomide (p¼0.3). Compared to P, ID-CY use was associated with higher median peak PB CD34+ cell count (63/ml vs. 160/ ml, P ¼ .01), CD34+ yield on day 1 of collection (6.5 x10 6 /kg vs.
11.7 x10 6 /kg, P ¼ .004), and total CD34+ cell yield (10.5 x10 6 / kg vs. 24.9 x10 6 /kg, P ¼ .001). Median numbers of apheresis sessions were 2.2 in each group (p¼0.9). No mobilization failures were seen in either group. There was no difference in the proportion of pts collecting 5x10 6 /kg CD34+ cells in either group (93% vs. 96%, P ¼ .6), but more pts in ID-CY cohort collected 10x10 6 /kg CD34+ cells (55% vs. 78%, P ¼ .02). Neutrophil engraftment was significantly faster (9.9 Abstracts / Biol Blood Marrow Transplant 19 (2013) S178eS193 S182
